New data from Assembly Biosciences look 'great,' says Jefferies
Assembly Biosciences presented this morning positive detailed results from its Phase IB study of oral ABI-H0731 in chronic hepatitis B patients, Jefferies analyst Michael Yee tells investors in a research note titled "New EASL Data Looks Great - Potent Efficacy Across HBV Populations - BUY." He believes the data show potent efficacy and dose response across hepatitis B patients as well as clean safety and tolerability. The analyst thinks Assembly "will increasingly be getting on the map" of big pharma and large biotech. The company remains an attractive takeover candidate for big companies in the anti-viral space as its drugs are "starting to play out," Yee contends. He keeps a Buy rating on Assembly Biosciences with a $75 price target.